SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares of Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of SiBone stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $18.46, for a total transaction of $369,200.00. Following the transaction, the director directly owned 16,057 shares of the company’s stock, valued at approximately $296,412.22. This trade represents a 55.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

SiBone Price Performance

Shares of SIBN opened at $18.04 on Thursday. The firm has a market capitalization of $800.06 million, a PE ratio of -53.06 and a beta of 0.66. The company’s 50-day moving average is $16.45 and its 200-day moving average is $15.14. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The company had revenue of $56.01 million during the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.31%. Equities analysts forecast that SiBone will post -0.44 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SIBN shares. Truist Financial restated a “buy” rating and set a $23.00 price objective (up from $21.00) on shares of SiBone in a research report on Tuesday. TD Cowen upped their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday. UBS Group increased their target price on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.29.

Institutional Trading of SiBone

Several hedge funds and other institutional investors have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd acquired a new position in shares of SiBone during the 4th quarter worth approximately $29,000. Versant Capital Management Inc raised its position in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares in the last quarter. Royal Bank of Canada raised its position in shares of SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after buying an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after buying an additional 1,941 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of SiBone in the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.